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Summary
This paper describes trends in treated problem drug use in Ireland between 2005 
and 2010. The analysis presented is based on data reported to the National Drug 
Treatment Reporting System (NDTRS) and to the Central Treatment List (CTL).
It is important to note that each record in the NDTRS database relates to a treatment 
episode (a case), and not to a person. This means that the same person could be 
counted more than once in the same calendar year if he/she had more than one 
treatment episode in that year.
The main findings of the analysis are:
The total number of cases in treatment for problem drug use increased over the 
reporting period, from 12,101 in 2005 to 16,429 in 2010.
The number of cases entering drug treatment each year and reported to the NDTRS 
increased by 52%, from 5,176 in 2005 to 7,878 in 2010. The clear spread and 
increase in treated drug use throughout the country reflect not only the extent of 
problem drug use but also an increase in treatment availability and compliance with 
the NDTRS.
Both the incidence (new cases) and the prevalence (all cases) of treated problem drug 
use among 15–64-year-olds living in Ireland increased consistently over the reporting 
period. The incidence increased from 70 cases per 100,000 in 2005 to 106 cases in 
2010. The number of new cases entering treatment is an indirect indicator of recent 
trends in problem drug use. The prevalence increased from 423 cases per 100,000 in 
2005 to 544 cases in 2010.
There was an increase in the total number of drug treatment services available in 
Ireland and participating in the NDTRS between 2005 and 2010. In the six-year 
period, the majority (68%) of cases received treatment in outpatient settings. Of the 
7,878 cases who entered treatment in 2010, the majority (58%) received counselling, 
32% received a brief intervention, 25% received methadone substitution and 23% 
attended education/awareness programmes.
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For the six-year period, the highest proportion (35%) of cases lived in the HSE Dublin Mid-Leinster Region; 
27% lived in the Dublin North East Region, 25% in the South and 13% in the West. There was a decrease 
in the proportions of cases in both Dublin regions and a parallel increase in the South and West regions, 
especially among previously treated cases.
Analysis by regional drugs task force (RDTF) area shows that the average annual incidence of treated drug 
use per 100,000 15–64-year-olds was highest in the South East RDTF area, followed by the North Dublin 
and the Southern RDTF areas.
Opiates (mainly heroin) were the most common problem drugs reported for all years, with the proportion 
of opiate users remaining stable between 2005 and 2008 but decreasing slightly in the following two 
years. The number of cases reporting cannabis as their main problem substance increased significantly 
over the reporting period, from 1,039 in 2005 to 1,893 in 2010. The number of cases reporting cocaine 
as their main problem substance peaked in 2007 and decreased slightly in the following years. Head 
shop compounds were reported as a main problem substance for the first time in 2009 (17 cases), with 
the number increasing significantly to 213 cases in 2010, when it exceeded the numbers reporting 
amphetamines, ecstasy and volatile inhalants.
The use of more than one problem substance continues to present a challenge to the treatment services. 
The vast majority (68%) of cases treated between 2005 and 2010 reported problem use of more than one 
substance. Cannabis, alcohol, cocaine and benzodiazepines were the most common additional problem 
drugs reported by all cases entering treatment. Information about the combinations of drugs used is 
important in terms of individual clients’ care plans, and in terms of policy initiatives.
Data show that half of the new cases entering treatment between 2005 and 2010 had started drug use 
at or before the age of 15 years. This finding highlights the need for prevention measures and service 
initiatives specially targeted at young teenagers in an attempt to delay initiation to drug use.
The proportion of previously treated cases who reported ever injecting decreased steadily over the reporting 
period, falling from 66% in 2005 to 48% in 2010; the proportion who were currently injecting, and the 
proportion who had ever shared injecting equipment also decreased. Although the proportion of new cases 
who reported ever injecting increased from 19% in 2005 to 22% in 2008, the overall downward trend 
in the proportions of injector cases is reflected among new cases in 2009 and 2010. The growth in harm 
reduction services over the reporting period is likely to have influenced this progress.
The profile of cases entering drug treatment remained stable over the reporting period; in general, problem 
drug users were male and in their twenties. The proportion of new cases aged under 18 years has increased 
since 2007 and reached 16% in 2010. The median age of all cases entering treatment increased from 26 
years in 2005 to 28 years in 2010. Another change was the drop in the proportion of cases who were in 
employment, from 22% in 2005 to 9% in 2010. This is most likely a reflection of the current economic 
climate, and highlights the continued importance of social and occupational reintegration interventions as 
part of the drug treatment process.
The significant increase in the total number of people requiring drug treatment services is a strong 
indication that problem drug use remains a pressing issue throughout the country, and presents complex 
and multiple challenges to those providing treatment.
An online appendix to this Trends Series paper, containing additional tables and figures with 
supplementary data, is available on the website of the National Documentation Centre on Drug Use at 
www.drugsandalcohol.ie/16381
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Introduction
National drug prevalence studies1,2 show that the proportion of adults (aged 15–64 years) in Ireland 
who reported using an illegal drug in their lifetime increased by 5%, from 19% in 2002/3 to 24% in 
2006/7. The proportion of young adults (aged 15–34 years) who reported ever using an illegal drug was 
higher, increasing from 26% in 2002/3 to 31% in 2006/7. The surveys show that cannabis was the most 
commonly used illicit drug and that more men than women reported having ever used an illicit drug.
The National Drug Treatment Reporting System (NDTRS) is an epidemiological database on treated drug 
and alcohol misuse in Ireland. It is co-ordinated by the National Health Information Systems staff of the 
Health Research Board (HRB) on behalf of the Department of Health.
Drug treatment data are viewed as an indirect indicator of drug and alcohol misuse, as well as a direct 
indicator of demand for treatment services. NDTRS data are used at national level (alcohol and drug data) 
and at European level (drug data) to provide information on the characteristics of clients entering treatment 
and on patterns of substance misuse, such as types of substance used and consumption behaviours. Drug 
data are ‘valuable from a public health perspective to assess needs, … and to plan and evaluate services’.3
The monitoring role of the NDTRS was recognised by the government in its document Building on 
experience: National Drugs Strategy 2001–2008.4 The collection and reporting of data to the NDTRS was one 
of the actions identified and agreed by the government for implementation. The National Drugs Strategy 
(interim) 2009–20165 recognised the positive impact of the NDTRS on the development of key indicators, 
stating that ‘the information provided through the NDTRS provide[s] significant insights into the patterns 
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of problem drug use’, and that ‘drug treatment data has also improved substantially through the NDTRS’ 
(p. 69). The National Drugs Strategy (NDS) also recommends the continuation and further development of 
data-collection systems, including the NDTRS (Action 49).
The HRB supplies service providers and policy makers with relevant data from the NDTRS to inform local 
and national substance misuse policy and planning. In recent years this information has been central to 
drugs strategy and policy decisions:
• In 1996 NDTRS data were used to identify a number of local areas with problematic heroin use.6 
These areas were later designated as local drugs task force (LDTF) areas, and task force teams have 
continued to provide strategic responses to drug misuse in their communities.
• In 2004 NDTRS data were used to describe treatment-seeking characteristics and behaviours of those 
aged under 18 years and to inform the deliberations of the Working Group on Treatment of under 18 
Year Olds.7
• In 2007 NDTRS data were used to inform some of the recommendations of the Working Group 
on Drugs Rehabilitation, and to assist the Working Group on Residential Services in estimating the 
number of residential places required to address severe alcohol and drug problems in Ireland.8
• In 2009 the Comptroller and Auditor General used data from the NDTRS in a special report on 
treatment and rehabilitation services provided for people with drug addiction.9
• In 2009 the NDS Steering Group used NDTRS data extensively to assess progress under the previous 
strategy.5
In addition, updated NDTRS data on trends in treated problem drug use over time are published in a 
regular and consistent manner, thus providing service providers and policy makers with the most recent 
figures available.
Background and methods
The NDTRS was established in 1990 in the Greater Dublin area and was extended in 1995 to cover all areas 
of the country. It was developed in line with the Pompidou Group’s Definitive Protocol10 and subsequently 
refined in accordance with the Treatment Demand Indicator Protocol. Originally designed to record drug 
misuse, the NDTRS recorded problematic use of alcohol only in cases where it was an additional problem 
substance, that is, where the client’s main reason for entering treatment was drug misuse, but he/she also 
reported problematic use of alcohol. In 2004, the remit of the NDTRS was extended to include cases where 
alcohol is recorded as the main or only reason for seeking treatment.
Treatment for problem substance use in Ireland is provided by statutory and non-statutory services, 
including residential centres, community-based addiction services and general practices.
For the purpose of the NDTRS, treatment is broadly defined as any activity that aims to ameliorate the 
psychological, medical or social state of individuals who seek help for their substance misuse problems. 
Clients who attend needle-exchange services are not included in this reporting system. Treatment options 
for problem substance use include one or more of the following: medication, psychiatric treatment, brief 
intervention, counselling (including cognitive behavioural therapy), medication-free therapy, family therapy, 
complementary therapy and/or life-skills training.
Compliance with the NDTRS requires that one form be completed for each new client coming for first 
treatment and for each previously treated client returning to treatment for problem substance use. Service 
providers at treatment centres throughout Ireland collect data on episodes of treatment, rather than on the 
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individual person treated each year. HRB staff then compile the anonymous, aggregated data, which are 
analysed and reported at national and European levels.
In order to analyse trends over time and thus provide an updated picture of treated problem drug use 
in Ireland, the last six years of available data were extracted from the NDTRS. A descriptive analysis of 
this subset of data was then done through frequencies and cross-tabulations of selected variables, and 
by calculating proportions and medians (for the age variables). Cases who reported alcohol as their main 
problem substance were excluded from this analysis (refer Trends paper 11).
The main elements of the reporting system in the context of this paper are defined as follows.
All treated cases – individuals who enter treatment for problem substance use at each treatment centre 
in a calendar year, including:
New cases treated – individuals who have never been treated for problem substance use;
Previously treated cases – individuals who were previously treated for problem substance use at any 
treatment centre and have returned to treatment for problem drug use in the reporting year;
Status unknown – individuals whose status with respect to previous treatment for problem substance use 
is not known.
The limitations of this analysis relate to the nature of the reporting system. Each record in the NDTRS 
database relates to a treatment episode (a case), and not to a person because there is currently no unique 
health identifier in Ireland. This means that the same person could be counted more than once in the 
reporting year if he/she had more than one treatment episode in that year.
While the coverage achieved by the NDTRS is very high overall, the number of services participating in the 
reporting system can vary over time. This makes small fluctuations in the numbers of cases more difficult to 
interpret.
The Central Treatment List (CTL) is another source of data on treated drug misuse. The CTL was established 
under Statutory Instrument No. 225, and is administered by the Drug Treatment Centre Board on behalf 
of the Health Service Executive (HSE). It is a complete register of all clients receiving methadone as a 
treatment for problem opiate use in Ireland. Each client is allocated a unique number and receives his/
her methadone from one source only. Every year, CTL staff provide the HRB with data on the number of 
individuals who were receiving methadone treatment on 31 December in the preceding year and carried 
forward to 1 January in the current year (continuous care cases). CTL data in relation to these cases were 
used in the calculation of prevalence rates presented in the first section of this analysis; continuous care 
cases are not included in the remaining sections of the analysis, which relate to NDTRS-recorded cases only.
Analysis
The analysis provides an outline of the following:
 incidence and prevalence;
 treatment provision;
 place of residence;
 substances;
 patterns of use;
 socio-economic characteristics.
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Incidence and prevalence
The total number of cases in treatment for problem drug use increased over the reporting period, from 
12,101 in 2005 to 16,429 in 2010. Over half (55%) of these were continuous care cases, that is, cases 
continuing in methadone treatment from the preceding calendar year and carried forward on 1 January 
each year, as reported by the CTL. The number of continuous care cases increased by 23%, from 6,925 in 
2005 to 8,551 in 2010 (Table 1).
The number of cases entering drug treatment each year and reported to the NDTRS increased by 52% 
over the reporting period, from 5,176 in 2005 to 7,878 in 2010. The number of new cases entering 
treatment increased by 59% over the period, rising from 2,054 in 2005 to 3,270 in 2010. New cases 
entering treatment are an indirect indicator of recent trends in problem drug use and treatment availability. 
Overall, the proportion of new cases increased slightly between 2005 and 2010. In 2010 they represented 
42% of cases entering treatment, on a par with the European average of 40% in 2008.12 The number of 
previously treated cases entering treatment increased by 49%, rising from 2,970 in 2005 to 4,424 in 2010. 
The growing number of individuals remaining in treatment or returning to treatment over the years is an 
indicator of a chronic situation and the need for addiction services into the future.
Table 1 Number of cases in treatment, by treatment status (NDTRS 2005–2010)
2005 2006 2007 2008 2009 2010
 n (%) n (%) n (%) n (%) n (%) n (%)
All cases in treatment 12101 12737 13597 14518 14933 16429
Cases continuing in 
methadone treatment 
from previous year* 6925 (57.2) 7262 (57.0) 7620 (56.0) 7942 (54.7) 8266 (55.4) 8551 (52.0)
Entries into treatment 
each year 5176 5475 5977 6576 6667 7878
Of which:
New cases 2054 (39.7) 2278 (41.6) 2476 (41.4) 2716 (41.3) 2970 (44.5) 3270 (41.5)
Previously treated cases 2970 (57.4) 3000 (54.8) 3309 (55.4) 3700 (56.3) 3565 (53.5) 4424 (56.2)
Treatment status 
unknown 152 (2.9) 197 (3.6) 192 (3.2) 160 (2.4) 132 (2.0) 184 (2.3)
* Data provided by the Central Treatment List.
Figure 1 presents the rates for the incidence (new cases) and prevalence (all cases) of treated problem drug 
use for the years 2005–2010, expressed per 100,000 of the population aged 15–64 years, based on census 
figures for 2005 and 2006 and Central Statistics Office (CSO) estimated figures for 2007 to 2010.13,14,15
The incidence increased consistently each year, rising from 70 cases per 100,000 in 2005 to 106 cases in 
2010. The number of new cases entering treatment is an indirect indicator of recent trends and points to 
an increase in drug use over the six-year period.
The prevalence also increased consistently during the reporting period, rising from 423 cases per 100,000 
in 2005 to 544 cases in 2010. This indicates that problem drug use is a chronic, recurring health condition 
that requires repeated episodes of treatment over time.
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Figure 1 Incidence and prevalence of treated problem drug use per 100,000 15–64-year-olds 
(NDTRS 2005–2010)
Treatment provision
There was an increase in the total number of drug treatment services available in Ireland and participating 
in the NDTRS between 2005 and 2010 (Table 2). In 2010, data were provided by 376 treatment services, 
an increase of 107 since 2005. The large majority of services were in outpatient settings, while a tenth of 
services were residential. The recruitment by NDTRS staff of many projects supported by LDTFs resulted in 
an increase in the number of low-threshold services reporting to the system in 2009 and 2010. The number 
of general practitioners (GPs) reporting cases entering treatment to the NDTRS fluctuated over the six-
year period; however, the overall number of GPs participating in the reporting system increased between 
2005 and 2010. This suggests that many GPs were providing methadone maintenance for stable long-term 
continuing care patients and therefore did not frequently enrol new patients. This view is supported by the 
increasing number of clients continuing in treatment from previous years and attending GP practices 
(Table 3).
Key points – incidence and prevalence
• Over half (55%) of all cases in treatment for problem drug use between 2005 and 2010 were 
continuous care cases.
• The number of cases entering drug treatment each year increased by 52% between 2005 and 2010.
• Overall, the proportion of new cases increased slightly between 2005 and 2010. In 2010 they 
represented 42% of cases entering treatment.
• Incidence increased from 70 cases per 100,000 in 2005 to 106 cases per 100,000 in 2010.
• Prevalence increased from 423 cases per 100,000 in 2005 to 544 cases per 100,000 in 2010.
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Table 2 Number of treatment services, by type of service provider (NDTRS 2005–2010)
2005 2006 2007 2008 2009 2010
All services 269 238 288 316 349 376
Outpatient 146 146 173 209 212 215
Inpatient 21 23 27 32 34 37
Low threshold 3 3 5 9 27 51
General practitioner 99 66 83 66 76 73
The majority (68%) of cases received treatment in outpatient settings. The number of cases entering 
treatment in outpatient services increased by 45%, from 3,828 cases in 2005 to 5,565 cases in 2010 (Table 
3). The number of cases entering residential treatment increased by 51%, from 817 cases in 2005 to 
1,232 cases in 2010. The number of cases entering treatment in GP settings and reported to the NDTRS 
decreased by 15% over the reporting period. This may be due to incomplete returns, but also reflects the 
cohort of stable clients attending GPs.
Table 3 Cases in treatment, by type of service provider (NDTRS and CTL 2005–2010)
2005 2006 2007 2008 2009 2010
n (%) n (%) n (%) n (%) n (%) n (%)
All cases in treatment 12101 12737 13597 14518 14933 16429
Outpatient 8154 (67.4) 8621 (67.7) 9262 (68.1) 9987 (68.8) 10146 (67.9) 10869 (66.2)
Inpatient 827 (6.8) 994 (7.8) 1071 (7.9) 1160 (8.0) 1077  (7.2) 1245 (7.6)
Low threshold* 289 (2.4) 233 (1.8) 125 (0.9) 159 (1.1) 368 (2.5) 828  (5.0)
General practitioner 2831 (23.4) 2889 (22.7) 3139 (23.1) 3212 (22.1) 3342 (22.4) 3487 (21.2)
Cases continuing in 
methadone treatment 
from previous years† 6925 7262 7620 7942 8266 8551
Outpatient 4326 (62.5) 4527 (62.3) 4730 (62.1) 4926 (62.0) 5141 (62.2) 5304 (62.0)
Inpatient 10 (0.1) 7 (0.1) 6 (0.1) 4 (0.1) 13 (0.2) 13 (0.2)
Low threshold 98 (1.4) 87 (1.2) 34 (0.4) 22 (0.3) 27 (0.3) 35 (0.4)
General practitioner 2491 (36.0) 2641 (36.4) 2850 (37.4) 2990 (37.6) 3085 (37.3) 3199 (37.4)
Previously treated and 
new cases entering 
treatment during year‡ 5176 5475 5977 6576 6667 7878
Outpatient 3828 (74.0) 4094 (74.8) 4532 (75.8) 5061 (77.0) 5005 (75.1) 5565 (70.6)
Inpatient 817 (15.8) 987 (18.0) 1065 (17.8) 1156 (17.6) 1064 (16.0) 1232 (15.6)
Low threshold 191 (3.7) 146 (2.7) 91 (1.5) 137  (2.1) 341 (5.1) 793 (10.1)
General practitioner 340 (6.6) 248 (4.5) 289 (4.8) 222 (3.4) 257 (3.9) 288 (3.7)
* Low-threshold services provide low-dose methadone or drop-in facilities only.
† Data provided by the Central Treatment List.
‡ NDTRS data.
The majority of treated cases received one initial treatment intervention; however, the proportion of cases 
receiving multiple interventions increased to 49% in 2010 from 36% in 2006.16 It is important to note that 
this analysis is based on data provided at the time of entry into treatment and therefore includes only initial 
treatment interventions. Other interventions that may be provided subsequently are recorded when clients 
are discharged.
Of the 7,878 cases entering treatment in 2010, 58% received individual or group counselling, 32% 
received a brief intervention, 25% received methadone substitution and 23% attended individual or group 
education/awareness programmes (Figure 2). There has been an increase in recent years in non-medical 
interventions, especially brief interventions and information/educational programmes.
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Figure 2  Percentage of treated cases by type of initial treatment intervention availed 
of (NDTRS 2010)
Place of residence
The annual numbers of treated cases were analysed by place of residence. A total of 37,749 cases entered 
treatment for problem drug use in the period 2005–2010, of whom 36,276 (96.1%) had a specified Irish 
address (Table 4). Very few cases each year reported their usual place of residence as outside Ireland, and a 
small proportion of cases were resident in Ireland but did not specify an address. The large majority of cases 
with an unknown place of residence were Dublin-based homeless people, who could not be assigned to a 
HSE region of residence (Dublin North East or Dublin Mid-Leinster).
Key points – treatment provision
• There was an increase in the total number of drug treatment services available in Ireland and 
participating in the NDTRS between 2005 and 2010.
• The majority (68%) of cases received treatment in outpatient settings.
• The majority (58%) of cases received counselling. There has been an increase in non-medical 
interventions, especially brief interventions and information/educational programmes.
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Table 4 Cases entering treatment, by place of residence (NDTRS 2005–2010)
2005 2006 2007 2008 2009 2010
n (%) n (%) n (%) n (%) n (%) n (%)
All cases 5176 5475 5977 6576 6667 7878
Ireland, specified address 4877 (94.2) 5238 (95.7) 5749 (96.2) 6322 (96.1) 6497 (97.5) 7593 (96.4)
Ireland, address not 
recorded 290 (5.6) 226 (4.1) 223 (3.7) 245 (3.7) 164 (2.5) 278 (3.6)
Outside Ireland 9 (0.2) 11 (0.2) 5 (0.1) 9  (0.1) 6 (0.1) 7 (0.1)
The following analysis and subsequent tables exclude cases not normally resident in Ireland and cases 
whose HSE region of residence is not known. When interpreting NDTRS data by geographical area, it is 
important to note that the numbers reported for each area may be influenced by treatment availability in 
the area, and by the extent to which services participated in the reporting system.
HSE region of residence
Table 5 presents cases entering treatment by HSE region of residence and by treatment status. In the six-
year period, the highest proportion (35%) of cases entering treatment lived in the HSE Dublin Mid-Leinster 
Region; 27% lived in the Dublin North East Region, 25% in the South and 13% in the West. There was a 
slight decrease in the proportions of cases in both Dublin regions and a parallel increase in the South and 
West regions between 2005 and 2010. The actual number of cases decreased in the Dublin North East and 
Dublin Mid-Leinster regions in 2009 for the first time in five years, but increased again slightly in 2010. In 
the same year, the highest proportion (34%) of cases entering treatment lived in the HSE South Region. 
The highest number of new cases lived in the South Region, with numbers increasing by 86% over the six-
year period, from 737 cases in 2005 to 1,369 cases in 2010. The second largest increase in new cases was 
in the West Region at 84%, followed by the Dublin Mid-Leinster Region (67%). The number of new cases 
increased in the Dublin North East Region up to 2008, but decreased every year since then.
Table 5 Cases entering treatment, by HSE region of residence and by treatment status (NDTRS 
2005–2010)
2005 2006 2007 2008 2009 2010
n (%) n (%) n (%) n (%) n (%) n (%)
All cases* 4877 5238 5749 6322 6497 7593
Dublin North East 1484 (30.4) 1522 (29.1) 1530 (26.6) 1742  (27.6) 1668 (25.7) 1781 (23.5)
Dublin Mid-Leinster 1824 (37.4) 1986 (37.9) 2137 (37.2) 2279 (36.0) 2191 (33.7) 2252 (29.7)
South 1099 (22.5) 1149 (21.9) 1264 (22.0) 1363 (21.6) 1812 (27.9) 2541 (33.5)
West 470 (9.6) 581 (11.1) 818 (14.2) 938 (14.8) 826 (12.7) 1019 (13.4)
New cases 1976 2229 2430 2658 2930 3207
Dublin North East 488 (24.7) 630 (28.3) 636 (26.2) 779 (29.3) 695 (23.7) 534 (16.7)
Dublin Mid-Leinster 452  (22.9) 541 (24.3) 583 (24.0) 622 (23.4) 714  (24.4) 755  (23.5)
South 737 (37.3) 724 (32.5) 752 (30.9) 761 (28.6) 1086 (37.1) 1369 (42.7)
West 299 (15.1) 334 (15.0) 459 (18.9) 496 (18.7) 435 (14.8) 549 (17.1)
Previously treated 
cases 2760 2825 3144 3510 3439 4217
Dublin North East 942 (34.1) 820 (29.0) 834 (26.5) 912 (26.0) 935 (27.2) 1202  (28.5)
Dublin Mid-Leinster 1317 (47.7) 1362 (48.2) 1483 (47.2) 1592 (45.4) 1415 (41.1) 1427 (33.8)
South 348 (12.6) 407 (14.4) 488 (15.5) 580 (16.5) 707 (20.6) 1132  (26.8)
West 153 (5.5) 236 (8.4) 339 (10.8) 426 (12.1) 382 (11.1) 456 (10.8)
Treatment status 
not known 141 184 175 154 128 169
* Excludes cases whose HSE region of residence is not known and cases not normally resident in Ireland.
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A more detailed analysis of treated problem drug use by HSE region of residence is available in the online 
appendix (www.drugsandalcohol.ie/16381).
Regional drugs task force area of residence
Data were further analysed by regional drugs task force (RDTF) area of residence. In order to adjust for 
variation in population size by geographical area, the actual incidence of treated drug use in each area was 
calculated using the average number of new cases over the six-year period living in each of the 10 RDTF 
areas; this average was divided by the population aged 15–64 years living in the respective RDTF areas, 
using the census figures for 2005 and 2006 and CSO estimated figures for 2007 to 2010.13, 14, 15
Between 2005 and 2010, the average annual incidence of treated drug use was highest in the South East 
RDTF area at 152 cases per 100,000, followed by the North Dublin area (101 cases) and the Southern area 
(93 cases). The incidence was lowest in the North West RDTF area at 52 cases per 100,000, the Western 
area (50 cases) and the East Coast area (38 cases).
In order to illustrate trends over time, the average annual incidence of treated problem drug use was 
examined for two distinct time periods, 2005–2007 (Figure 3) and 2008–2010 (Figure 4), by RDTF area of 
residence.
In the 2005–2007 period, the average annual incidence of treated drug use ranged from 31 cases per 
100,000 in the East Coast RDTF area to 131 cases in the South East RDTF area.
In the 2008–2010 period, the average annual incidence of treated drug use ranged from 44 cases per 
100,000 in the East Coast RDTF area to 174 cases in the South East area. The incidence increased in all 
areas compared to the previous three-year period except in the North Eastern RDTF area. No RDTF area 
had an average annual incidence of less than 40 cases per 100,000 in the 2008–2010 period, while there 
were two such areas in the earlier period.
The two maps (Figures 3 and 4) clearly show both the spread and the increase in cases of treated drug 
use throughout the country. This reflects not only the extent of problem drug use but also an increase in 
treatment availability and in compliance with the NDTRS. The highest proportional increase between the 
two three-year periods occurred in the Western RDTF area, where the average annual incidence increased 
by 66%, from 38 cases in 2005–2007 to 62 cases in 2008–2010. The incidence increased by 48% in 
the Southern RDTF area and by 41% in the East Coast area. The lowest proportional increase was in the 
Midland RDTF area, at 12%, and the incidence decreased by 16% in the North Eastern area.
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Figure 3 Average annual incidence of treated problem drug use per 100,000 15–64-year-olds, by 
regional drugs task force area of residence (NDTRS 2005–2007)
 NB: Incidence rates are affected by level of participation in the NDTRS.
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Figure 4 Average annual incidence of treated problem drug use per 100,000 15–64-year-olds, by 
regional drugs task force area of residence (NDTRS 2008–2010)
 NB: Incidence rates are affected by level of participation in the NDTRS.
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Problem substances
Main problem substance
In the six-year period, opiates, mainly heroin, were the most common main problem drugs (61%), followed 
by cannabis (21%) and cocaine (11%). The proportion of opiate users remained stable between 2005 
and 2008, but decreased slightly in 2009 and 2010. The proportion of cases reporting cannabis as their 
main problem substance decreased between 2005 and 2007 but increased steadily thereafter, reaching its 
highest level in 2010 at 25% (1,893 cases) (Table 6) . Following a steady increase to a peak in 2007 (777 
cases), the number of cases reporting cocaine as their main problem substance decreased in the subsequent 
two years and remained stable in 2010 (Figure 5).
While the number of opiate cases increased overall, the proportion of opiate users among previously treated 
cases decreased over the reporting period, from 83% in 2005 to 72% in 2010. A growing proportion 
of cases returning to treatment reported problem use of drugs other than opiates, such as cannabis or 
benzodiazepines.
Substances categorised as ‘other’ comprised: substances bought in head shops (58%); sedatives other 
than benzodiazepines (15%); hallucinogenic substances such as lysergic acid (7%); and other unspecified 
medication (6%). The significant increase in the number of new cases reporting an ‘other’ drug as their 
main problem substance is mainly due to the appearance of head shop substances in treatment data. In 
2010, 213 cases reported a head shop substance as their main problem drug (accounting for 77% of the 
‘other’ category), while there were only 17 cases in 2009. 
Key points – place of residence
• Between 2005 and 2010, the highest proportion of cases lived in the HSE Dublin Mid-Leinster Region 
(35%); 27% lived in the Dublin North East, 24% in the South and 13% in the West regions.
• There was a slight decrease in the proportion of cases in both HSE Dublin regions and a parallel 
increase in the South and West HSE regions.
• The average annual incidence was highest in the South East RDTF area, followed by the North Dublin 
and North Eastern areas. It was lowest in the North West, Western and East Coast areas.
• The clear spread and increase in treated drug use throughout the country reflect not only the 
extent of problem drug use but also an increase in treatment availability and in compliance with the 
NDTRS.
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Table 6 Main problem drug used by cases entering treatment, by treatment status (NDTRS 2005–
2010)
2005 2006 2007 2008 2009 2010
n (%) n  (%) n (%) n (%) n (%) n (%)
All cases 4877 5238 5749 6322 6497 7593
Opiates 3094 (63.4) 3326 (63.5) 3627 (63.1) 4004 (63.3) 3862 (59.4) 4300 (56.6)
Ecstasy 124 (2.5) 95 (1.8) 129 (2.2) 103 (1.6) 64 (1.0) 48 (0.6)
Cocaine 467 (9.6) 552 (10.5) 777 (13.5) 762 (12.1) 696 (10.7) 698 (9.2)
Amphetamines 36 (0.7) 30 (0.6) 39 (0.7) 36 (0.6) 33 (0.5) 56 (0.7)
Benzodiazepines 75 (1.5) 96 (1.8) 163 (2.8) 167  (2.6) 260 (4.0) 292  (3.8)
Volatile inhalants 27 (0.6) 23 (0.4) 32 (0.6) 28 (0.4) 21 (0.3) 31 (0.4)
Cannabis 1039 (21.3) 1097 (20.9) 963 (16.8) 1192  (18.9) 1519 (23.4) 1893 (24.9)
Other 15 (0.3) 19 (0.4) 19 (0.3) 30 (0.5) 42 (0.6) 275 (3.6)
New cases 1976 2229 2430 2658 2930 3207
Opiates 722 (36.5) 913 (41.0) 1037 (42.7) 1169 (44.0) 1221  (41.7) 1172 (36.5)
Ecstasy 92 (4.7) 65 (2.9) 86 (3.5) 66 (2.5) 47 (1.6) 21 (0.7)
Cocaine 275 (13.9) 342 (15.3) 466 (19.2) 447 (16.8) 417 (14.2) 382 (11.9)
Amphetamines 22 (1.1) 21 (0.9) 25  (1.0) 26 (1.0) 22 (0.8) 33 (1.0)
Benzodiazepines 42 (2.1) 50 (2.2) 85 (3.5) 74 (2.8) 137 (4.7) 140 (4.4)
Volatile inhalants 21 (1.1) 19 (0.9) 24 (1.0) 16 (0.6) 14 (0.5) 25 (0.8)
Cannabis 794 (40.2) 809 (36.3) 695 (28.6) 845 (31.8) 1047 (35.7) 1253 (39.1)
Other 8 (0.4) 10 (0.4) 12 (0.5) 15 (0.6) 25 (0.9) 181 (5.6)
Previously 
treated cases 2760 2825 3144 3510 3439 4217
Opiates 2281 (82.6) 2281  (80.7) 2450  (77.9) 2723  (77.6) 2566  (74.6) 3034 (71.9)
Ecstasy 30 (1.1) 29 (1.0) 42 (1.3) 36 (1.0) 17 (0.5) 23 (0.5)
Cocaine 175 (6.3) 194 (6.9) 293  (9.3) 300  (8.5) 261 (7.6) 304  (7.2)
Amphetamines 14 (0.5) 9 (0.3) 14 (0.4) 10 (0.3) 11  (0.3) 20 (0.5)
Benzodiazepines 30 (1.1) 40  (1.4) 72 (2.3) 87 (2.5) 118  (3.4) 143 (3.4)
Volatile inhalants 5 (0.2) 3 (0.1) 7 (0.2) 12 (0.3) 7 (0.2) 5  (0.1)
Cannabis 219 (7.9) 260 (9.2) 259 (8.2) 330 (9.4) 443 (12.9) 597 (14.2)
Other 6 (0.2) 9 (0.3) 7 (0.2) 12 (0.3) 16 (0.5) 91 (2.2)
Treatment 
status unknown 141 184 175 154 128 169
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Figure 5  All cases: main problem drug (NDTRS 2005–2010) 
Among new cases, the numbers reporting an opiate as their main problem drug increased by 62%, from 
722 in 2005 to 1,172 in 2010 (Figure 6). Cannabis was increasingly reported as a main problem drug 
between 2005 and 2010, with the numbers increasing by 48% in the last two years. In 2010, cannabis 
became the most common main problem drug reported by new cases, ahead of opiates for the first time 
since 2005. The number of new cases reporting ecstasy as their main problem drug dropped by over 77% 
between 2005 and 2010. The highest proportional increase (233%) over the six-year period was among 
new cases reporting a benzodiazepine as their main problem drug.
Figure 6 New cases: main problem drug (NDTRS 2005–2010)
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Trends in the main problem drugs reported are in line with those at European level, where the three most 
common main problem drugs reported by new cases in 2009 were the same as in Ireland. However, the 
proportion of new opiate cases was higher in Ireland (42%, compared to 31% in the EU). The proportion 
of new cocaine cases was lower (14%, compared to 23% in the EU). The proportion of new cannabis cases 
was 36% in Ireland and 33% in the EU.17
The proportions of new cases reporting each substance as their main problem drug differed according to 
gender (Figure 7). Over the six-year period, cannabis was the main problem drug most commonly reported 
by new male cases (39%), just ahead of opiates (37%) and followed by cocaine (17%). The majority (52%) 
of new female cases reported an opiate as their main problem drug, followed by cannabis (24%) and 
cocaine (10%). The proportion of new cases reporting ecstasy was just about the same for both genders; 
3% of males and 6% of females reported a benzodiazepine as their main problem drug.
Figure 7 New cases: main problem drug by gender (NDTRS 2005–2010)
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Key points – main problem substance
• In the period 2005–2010, opiates were the most common problem drug (61%), followed by 
cannabis (21%) and cocaine (11%).
• The proportion of opiate users remained stable between 2005 and 2008, but decreased in 2009 and 
2010.
• The number of cases reporting cannabis as their main problem substance increased significantly, with 
cannabis becoming the most common problem drug reported by new cases in 2010.
• Since 2007, the number of cases reporting cocaine as a main problem drug has decreased. There 
was also a drop in the number of ecstasy cases.
• In 2010, nearly 5% of new cases reported a head shop substance as their main problem drug.
• Among new cases, benzodiazepines accounted for the highest proportional increase over the 
reporting period.
• Cannabis was the main problem drug most commonly reported by new male cases, while the 
majority of new female cases reported an opiate as their main problem drug.
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Additional problem substances
The majority (68%) of treated cases between 2005 and 2010 reported problem use of more than one 
substance. The proportion of cases reporting multiple problem substances fluctuated over the reporting 
period, with the highest proportion (71%) recorded in 2006 and the lowest proportion (65%) recorded in 
2010 (Table 7). The use of several substances increases the complexity of cases, and is generally associated 
with poorer treatment outcomes.
Table 7 Use of more than one drug, by treatment status (NDTRS 2005–2010)
2005 2006 2007 2008 2009 2010
n (%) n (%) n (%) n (%) n (%) n (%)
All cases 4877 5238 5749 6322 6497 7593
Using more than one drug 3401 (69.7) 3732 (71.2) 3850 (67.0) 4430 (70.1) 4324 (66.6) 4913 (64.7)
New cases 1976 2229 2430 2658 2930 3207
Using more than one drug 1374 (69.5) 1556 (69.8) 1612 (66.3) 1820 (68.5) 1926 (65.7) 2018 (62.9)
Previously treated cases 2760 2825 3144 3510 3439 4217
Using more than one drug 1934 (70.1) 2044 (72.4) 2144 (68.2) 2532 (72.1) 2336 (67.9) 2809 (66.6)
Treatment status unknown 141 184 175 154 128 169
Of the cases who entered treatment during the period under review, 28% reported problem use of two 
substances, 22% reported problem use of three, and 18% reported problem use of four. Previously treated 
and new cases showed similar trends.
Table 8 presents the additional problem substances used by cases reporting more than one problem 
substance. Cannabis, alcohol, cocaine and benzodiazepines were the most common additional problem 
drugs reported by cases entering treatment in the period 2005–2010. Cannabis was top of this list 
between 2005 and 2007, replaced by alcohol in the subsequent years. In 2010, alcohol was reported as 
an additional substance by 2,026 cases, a 78% increase on the 2005 figure of 1,136. Benzodiazepines 
became the third most common additional drug in 2010, ranking ahead of cocaine. Figure 8 provides a 
visual outline of these trends. A growing number of cases reported the use of drugs in the category ‘Other’, 
overtaking the amphetamine category from 2008 onwards. Ten per cent of all additional drugs reported in 
2010 were in the category ‘Other’, and comprised substances purchased in head shops (59%), sedatives 
other than benzodiazepines (19%, most of which are those colloquially known as ‘Z-drugs’), hallucinogenic 
substances such as lysergic acid (9%) and other medication (6%).
The additional substances most frequently reported by previously treated cases were cannabis (40%), 
cocaine (38%) and benzodiazepines (37%). Alcohol was fourth in the ranking, at 32%, with the number 
increasing by a substantial 125% over the six-year period, from 439 cases in 2005 to 988 cases in 2010. 
The proportion of previously treated cases reporting ecstasy as an additional problem substance fluctuated 
between 10% and 12% during the period.
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Table 8 Additional problem substances, by treatment status (NDTRS 2005–2010)
2005 2006 2007 2008 2009 2010
n (%) n (%) n (%) n (%) n (%) n (%)
All cases* 3401 3732 3850 4430 4324 4913
Opiates 686 (20.2) 707 (18.9) 661 (17.2) 777 (17.5) 684 (15.8) 816 (16.6)
Ecstasy 645 (19.0) 597 (16.0) 640 (16.6) 638 (14.4) 626 (14.5) 560 (11.4)
Cocaine 1144 (33.6) 1384 (37.1) 1386 (36.0) 1631  (36.8) 1448 (33.5) 1393 (28.4)
Amphetamines 195 (5.7) 205 (5.5) 181  (4.7) 131  (3.0) 143 (3.3) 156 (3.2)
Benzodiazepines 963 (28.3) 1067 (28.6) 947 (24.6) 1424 (32.1) 1289 (29.8) 1608 (32.7)
Volatile inhalants 31 (0.9) 23  (0.6) 24  (0.6) 23 (0.5) 30  (0.7) 18 (0.4)
Cannabis 1417 (41.7) 1596 (42.8) 1637 (42.5) 1809 (40.8) 1545 (35.7) 1694 (34.5)
Alcohol 1136 (33.4) 1466 (39.3) 1529 (39.7) 1826 (41.2) 1931 (44.7) 2026 (41.2)
Other 113  (3.3) 98 (2.6) 142 (3.7) 172 (3.9) 213 (4.9) 476 (9.7)
New cases 1374 1556 1612 1820 1926 2018
Opiates 150 (10.9) 194 (12.5) 172 (10.7) 237 (13.0) 214 (11.1) 187 (9.3)
Ecstasy 407 (29.6) 394 (25.3) 394 (24.4) 370 (20.3) 367 (19.1) 285 (14.1)
Cocaine 401 (29.2) 478 (30.7) 505 (31.3) 582 (32.0) 547 (28.4) 492 (24.4)
Amphetamines 123 (9.0) 113 (7.3) 103 (6.4) 69 (3.8) 91 (4.7) 80 (4.0)
Benzodiazepines 198 (14.4) 257 (16.5) 255 (15.8) 423 (23.2) 417 (21.7) 498 (24.7)
Volatile inhalants 20 (1.5) 14 (0.9) 14 (0.9) 9  (0.5) 14 (0.7) 8 (0.4)
Cannabis 527 (38.4) 583 (37.5) 682 (42.3) 703 (38.6) 671 (34.8) 718 (35.6)
Alcohol 663 (48.3) 846 (54.4) 821 (50.9) 921 (50.6) 1047 (54.4) 1004 (49.8)
Other 57 (4.1) 58 (3.7) 63 (3.9) 90 (4.9) 97 (5.0) 257 (12.7)
Previously treated cases 1934 2044 2144 2532 2336 2809
Opiates 515 (26.6) 469 (22.9) 471 (22.0) 525 (20.7) 464 (19.9) 617 (22.0)
Ecstasy 223 (11.5) 197 (9.6) 237 (11.1) 260 (10.3) 253 (10.8) 270 (9.6)
Cocaine 717 (37.1) 848 (41.5) 851 (39.7) 1026 (40.5) 884 (37.8) 880 (31.3)
Amphetamines 69 (3.6) 88 (4.3) 77 (3.6) 59 (2.3) 50 (2.1) 74 (2.6)
Benzodiazepines 739 (38.2) 787  (38.5) 677 (31.6) 980 (38.7) 855 (36.6) 1086 (38.7)
Volatile inhalants 9 (0.5) 9 (0.4) 9 (0.4) 14 (0.6) 12 (0.5) 10 (0.4)
Cannabis 844 (43.6) 942 (46.1) 910 (42.4) 1071 (42.3) 858 (36.7) 946  (33.7)
Alcohol 439 (22.7) 582 (28.5) 670 (31.3) 872  (34.4) 852 (36.5) 988 (35.2)
Other 53 (2.7) 38  (1.9) 78 (3.6) 77 (3.0) 111 (4.8) 214 (7.6)
Treatment status unknown 93 132 94 78 62 86
* All cases who reported use of one, two or three additional drugs.
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 2005 2006 2007 2008 2009 2010
Opiates 686 707 661 777 684 816
Ecstasy 645 597 640 638 626 560
Cocaine 1144 1384 1386 1631 1448 1393
Benzodiazepines 963 1067 947 1424 1289 1608
Cannabis 1417 1596 1637 1809 1545 1694
Alcohol 1136 1466 1529 1826 1931 2026
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Figure 8 All cases: additional problem substances (NDTRS 2005–2010)
Alcohol (51%), cannabis (38%) and cocaine (29%) were the additional substances most frequently reported 
by new cases. Alcohol ranked first in each year and increased its lead significantly after 2007, widening the 
gap between it and cannabis, the second most common additional drug (Figure 9). There was an increase 
of 152% in the number reporting a benzodiazepine as an additional substance, causing it to move up the 
ranking from fifth place in 2007 to third place in 2010. The number of cases reporting ecstasy decreased 
over the years. 
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 2005 2006 2007 2008 2009 2010
Opiates 150 194 172 237 214 187
Ecstasy 407 394 394 370 367 285
Cocaine 401 478 505 582 547 492
Benzodiazepines 198 257 255 423 417 498
Cannabis 527 583 682 703 671 718
Alcohol 663 846 821 921 1047 1004
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Figure 9 New cases: additional problem substances (NDTRS 2005–2010)
The association between main problem drug and additional problem drugs among new cases entering 
treatment was examined for the period 2005–2010 (Table 9). The pattern of additional drugs used was 
linked to the main problem drug. For example, where an opiate was the main problem drug (first number 
column), the most common additional problem drugs were cannabis (54%), followed by benzodiazepines 
(35%) and cocaine (34%); whereas where cannabis was the main problem drug (second last column), the 
most common additional drugs were alcohol (74%), followed by cocaine (38%) and ecstasy (32%). In fact, 
the proportion of new cases reporting alcohol as an additional problem substance was over 50% for all 
substances except opiates and ‘other’ substances. These data emphasise the link between alcohol and illicit 
drug use.
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Table 9 New cases: main problem substance and associated additional problem substances 
(NDTRS 2005–2010)
Main problem drug
Opiates Ecstasy Cocaine
Amphet
amines
Benzo-
diazepines
Volatile 
inhalants Cannabis Other
New cases 3912 308 1848 120 385 56 3505 172
Additional problem 
drug(s) used* n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Opiates 728 (18.6)† 11 (3.6) 122 (6.6) 4 (3.3) 81 (21.0) 3 (5.4) 195 (5.6) 10 (5.8)
Ecstasy 325 (8.3) 0 (0.0) 625 (33.8) 52 (43.3) 54  (14.0) 4 (7.1) 1136 (32.4) 21 (12.2)
Cocaine 1321 (33.8) 143 (46.4) 31 (1.7)† 44  (36.7) 107 (27.8) 3 (5.4) 1321  (37.7) 35 (20.3)
Amphetamines 76 (1.9) 64 (20.8) 124 (6.7) 0 (0.0) 7  (1.8) 0 (0.0) 299 (8.5) 9 (5.2)
Benzodiazepines 1350 (34.5) 17 (5.5) 223 (12.1) 4 (3.3) 15 (3.9)† 2 (3.6) 413 (11.8) 24 (14.0)
Volatile inhalants 9 (0.2) 1  (0.3) 9 (0.5) 0 (0.0) 4  (1.0) 3 (5.4)† 53 (1.5) 0  (0.0)
Cannabis 2116 (54.1) 182 (59.1) 1160 (62.8) 59  (49.2) 211  (54.8) 36 (64.3) 26 (0.7)† 94 (54.7)
Alcohol 1072 (27.4) 158 (51.3) 1074 (58.1) 63 (52.5) 235 (61.0) 40 (71.4) 2575 (73.5) 85 (49.4)
Other 193 (4.9) 14  (4.5) 81 (4.4) 7 (5.8) 28 (7.3) 1 (1.8) 276 (7.9) 22 (12.8)
* By cases reporting use of one, two or three additional drugs.
† Additional problem drug(s) used may be a form of drug in the same family as the main problem drug.
Patterns of use
Table 10 presents the median age of new cases at significant milestone indicators, by the most common 
main problem substances. Half of new cases started their drug use at or before the age of 15. The median 
age at which new cases first used any drug was younger for cannabis cases, at 14 years, and older for 
ecstasy cases, at 16 years. The median age was 15 years for opiate, cocaine and benzodiazepine cases. 
This means that 50% of those cases first used drugs at or before the age of 15.
While the median age at first use of any drug was similar for all substances, there were differences in the 
median age at first use of the main problem drug reported. The median age at which opiate users first used 
any drug was 15 years, but the median age at which they first used opiates was 20 years. This indicates that 
many of those reporting opiates as a main problem substance started using other drugs before moving to 
opiates. For cannabis cases the median age at first use of any drug (14 years) and at first use of cannabis (14 
years) was the same, indicating that cannabis probably was the first drug ever used by many cases.
Key points – additional problem substances
• The majority (68%) of cases entering treatment between 2005 and 2010 reported problem use of 
more than one substance.
• Cannabis, alcohol, cocaine and benzodiazepines were the most common additional problem 
substances reported by all cases entering treatment.
• Alcohol, cannabis and cocaine were the additional substances most frequently reported by new 
cases, although benzodiazepines became the third most common additional substance in 2010.
• The proportion of new cases reporting alcohol as an additional problem substance was over 50% for 
all substances except opiates and ‘other’ substances, which highlights the link between alcohol and 
illicit drug use.
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Half of the cases reporting a benzodiazepine as their main problem substance started to use 
benzodiazepines before the age of 18, but these cases show the widest range for age at first use, at 
between 13 and 40 years.
The median age at which new cases first sought treatment for their problem drug use varied between 20 
and 28 years.
The number of years between first use of the main problem substance and first entry into treatment was 
calculated by deducting the age at first use from the age of new cases entering treatment. Half of the new 
opiate, cannabis and benzodiazepine cases first entered treatment five years after they first used their main 
problem substance. The time lag is slightly shorter for new ecstasy and cocaine cases, with three and four 
years respectively between first use and first treatment.
Table 10 New cases: median age at significant points, and time in years between first use of main 
problem substance and entry into treatment (NDTRS 2005–2010)
Age first used 
any drug
Age first used 
main problem 
substance
Age first 
sought 
treatment
Years between 
first use of 
main problem 
substance and 
first entry to 
treatment
Median age/time (range*) in years
New cases 15 (11–24) 17  (12–31) 24  (15–41) 5 (0–19)
Most common main 
problem substance
Opiates 15  (11–27) 20 (14–35) 28 (19–44) 5 (1–20)
Ecstasy 16 (12–22) 17 (13–24) 21  (16–33) 3 (0–14)
Cocaine 15 (11–23) 18 (14–30) 24 (18–38) 4  (1–15)
Cannabis 14 (11–20) 14  (11–20) 20 (15–37) 5 (1–21)
Benzodiazepines 15 (11–39) 18  (13–40) 25 (16–54) 5 (0–23)
* Age/time range presented is 5th percentile to 95th percentile (90% of cases are included within this range).
Risk behaviours
Table 11 presents the number and proportion of cases who reported having ever injected (injector cases) 
as well as their characteristics. While the actual number of injector cases increased in all years except 2006 
and 2009, the proportion decreased each year during the period under review, from 46% in 2005 to 34% 
in 2010. This finding is in line with trends in other European countries.12,17 The proportion of previously 
treated cases who reported ever injecting decreased steadily over the reporting period, from 66% in 2005 
to 48% in 2010. 
The median age at which injector cases first started their drug use remained stable, at 14 years, over the 
reporting period, and was the same for new and previously treated cases. This means that half of the 
injector cases started their drug use at or before the age of 14.
The median age at which previously treated cases first injected was 19 years in the period 2005–2007, and 
20 years in the period 2008–2010. The median age at which new injector cases first injected was slightly 
higher; in 2010, half of new injector cases started injecting at or before the age of 22 years. These data 
suggest a trend towards an increasing interval between the start of illicit drug use and first injecting.
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Table 11  Risk behaviours by treatment status (NDTRS 2005–2010)
2005 2006 2007 2008 2009 2010
n (%) n (%) n (%) n (%) n (%) n (%)
All cases* 4707 5037 5522 6107 6270 7236
Ever injected 2164 (46.0) 2149 (42.7) 2331 (42.2) 2471 (40.5) 2341  (37.3) 2428 (33.6)
Injector cases 2164 2149 2331 2471 2341 2428
Of which:
Ever shared 1305 (60.3) 1268 (59.0) 1333 (57.2) 1339  (54.2) 1195 (51.0) 1246 (51.3)
Currently injecting 918 (42.4) 976 (45.4) 986 (42.3) 1017 (41.2) 877 (37.5) 855 (35.2)
Median age (range†) started 
drug use, in years 14 (11–20) 14 (10–20) 14 (10–19) 14 (10–20) 14 (10–19) 14 (10–20)
Median age (range) started 
injecting, in years 19 (14–30) 19 (15–30) 20 (15–30) 20 (15–32) 20 (15–32) 20 (15–32)
New cases 1940 2174 2371 2605 2856 3075
Ever injected 358  (18.5) 424 (19.5) 477 (20.1) 561  (21.5) 576  (20.2) 445 (14.5)
Injector cases 358 424 477 561 576 445
Of which:
Ever shared 160 (44.7) 189 (44.6) 228 (47.8) 229 (40.8) 242 (42.0) 177 (39.8)
Currently injecting 189  (52.8) 216  (50.9) 234 (49.1) 241 (43.0) 255 (44.3) 213 (47.9)
Median age (range) started 
drug use, in years 14 (11–22) 14 (11–22) 14 (10–20) 14 (10–20) 14 (10–20) 14  (11–24)
Median age (range) started 
injecting, in years 20 (15–31) 20 (15–32) 21 (15–33) 21 (15–33) 21 (15–33) 22 (15–35)
Previously treated cases 2639 2703 3023 3405 3315 4023
Ever injected 1745 (66.1) 1638 (60.6) 1798 (59.5) 1875 (55.1) 1737 (52.4) 1946 (48.4)
Injector cases 1745 1638 1798 1875 1737 1946
Of which:
Ever shared 1112 (63.7) 1040 (63.5) 1082 (60.2) 1100  (58.7) 947 (54.5) 1056 (54.3)
Currently injecting 704 (40.3) 727 (44.4) 717 (39.9) 764 (40.7) 614 (35.3) 628 (32.3)
Median age (range) started 
drug use, in years 14 (11–20) 14 (11–20) 14 (10–19) 14 (10–20) 14 (10–19) 14  (10–19)
Median age (range) started 
injecting, in years 19 (14–30) 19 (15–29) 19 (15–30) 20 (15–31) 20 (15–31) 20 (15–31)
Treatment status unknown 128 160 128 97 99 138
* Excludes cases whose injecting status is not known.
† Age range presented is the 5th to 95th percentile (90% of cases are included within this range).
Although the proportion of new cases who reported ever injecting increased slightly, from 19% in 2005 
to 22% in 2008, the overall downward trend in the proportions of injector cases is reflected among new 
cases in the later years of the review period, with a slight decrease in 2009 (to 20%) followed by a sharper 
drop in 2010 (to 15%) (Figure 10). The proportion of new cases reporting injecting in the four weeks prior 
to entering treatment decreased from 10% in 2005 to 7% in 2010. The proportion of new cases reporting 
having shared injecting equipment peaked in 2007 (at 10%) and decreased in subsequent years.
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Figure 10 New cases: reported risk behaviours (NDTRS 2005–2010)
Figure 11 shows the decrease in the proportion of injectors and in the sharing of injecting equipment as 
reported by previously treated cases between 2005 and 2010. This decrease is likely to be the result of the 
more widespread adoption of harm reduction policies and practices in recent years.
Figure 11 Previously treated cases: reported risk behaviours (NDTRS 2005–2010)
 2005 2006 2007 2008 2009 2010
Ever injected 18.5 19.5 20.1 21.5 20.2 14.5
Ever shared 8.2 8.7 9.6 8.8 8.5 5.8
Currently injecting 9.7 9.9 9.9 9.3 8.9 6.9
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Key points – patterns of use
• Half of new cases entering treatment between 2005 and 2010 started their drug use at or before the 
age of 15.
• Five years was the average time lag between first use of main problem drug and first entry into 
treatment.
• Among previously treated cases there was a decrease in injecting behaviours, including the sharing 
of injecting equipment, between 2005 and 2010. A similar trend was noted among new cases from 
2008 onwards.
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Socio-economic characteristics
Table 12 presents socio-economic characteristics of treated cases. In the six-year period, the median age 
of cases increased from 26 years in 2005 to 28 years in 2010. The trend was similar for previously treated 
cases (from 28 years in 2005 to 30 years in 2010) and for new cases (from 23 years in 2005 to 24 years in 
2010). Just over 8% of cases were under 18 years of age. The proportion of new cases under 18 years of 
age decreased between 2005 and 2006 but increased again in the subsequent four years, to reach 16% in 
2010. Cases in that age group represented just over 3% of previously treated cases, with a slight increase 
throughout the period under review.
Though small, the proportion of cases who reported being homeless increased between 2005 and 2008, 
when it peaked at 6%, and then decreased to its lowest level, at 4%, in 2010. Overall, the incidence of 
homelessness was higher among previously treated cases (6%) than among new cases (4%).
The number of non-Irish nationals entering treatment increased during the period under review. In 2010, 
5% of new cases reported a nationality other than Irish. This increase may have implications for service 
provision as the majority of treatment interventions rely heavily on verbal communication, and there may 
be a language barrier if clients are not fluent in English.
Overall, the proportion of cases who had left mainstream education before the age of 14 remained 
relatively stable at 20%, with a slight decrease to 19% in 2010. Five per cent of cases were still attending 
school, with a higher proportion among new cases (10%) than among previously treated cases (1%).
The proportion of all cases who reported being employed dropped from 22% in 2005 to 9% in 2010.
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Table 12 Socio-economic characteristics of cases, by treatment status (NDTRS 2005–2010)
2005 2006 2007 2008 2009 2010
n (%) n (%) n (%) n (%) n (%) n (%)
All cases 4877 5238 5749 6322 6497 7593
Median age (range*) 26 (16–41) 27 (17–42) 27 (17–42) 28 (16–43) 28 (16–44) 28 (16–44)
Under 18 years 404 (8.3) 363 (6.9) 423  (7.4) 493 (7.8) 592 (9.1) 707 (9.3)
Male 3613 (74.1) 4018 (76.7) 4386  (76.3) 4641 (73.4) 4805 (74.0) 5508  (72.5)
Living with parents and/or 
family 2536 (52.0) 2664 (50.9) 2853 (49.6) 3175  (50.2) 3192 (49.1) 3681  (48.5)
Homeless 217 (4.4) 303  (5.8) 300 (5.2) 382 (6.0) 315  (4.8) 297 (3.9)
Non-Irish national 162 (3.3) 195  (3.7) 240  (4.2) 251  (4.0) 276 (4.2) 317  (4.2)
Early school leaver 986  (20.2) 1059 (20.2) 1149 (20.0) 1324 (20.9) 1315 (20.2) 1413 (18.6)
Still at school 275  (5.6) 222 (4.2) 252 (4.4) 303 (4.8) 340 (5.2) 449  (5.9)
Employed (aged 16–64) 1025 (21.8) 1071 (21.0) 1059  (18.9) 921 (15.0) 689 (10.9) 670 (9.1)
New cases 1976 2229 2430 2658 2930 3207
Median age (range) 23 (15–39) 24 (15–40) 24  (16–41) 25 (15–43) 25 (15–43) 24 (16–42)
Under 18 years 326 (16.5) 285 (12.8) 328 (13.5) 374 (14.1) 466 (15.9) 516 (16.1)
Male 1542 (78.0) 1759  (78.9) 1877  (77.2) 2011  (75.7) 2261  (77.2) 2414 (75.3)
Living with parents and/or 
family 1175 (59.5) 1227  (55.0) 1359  (55.9) 1519 (57.1) 1629 (55.6) 1752  (54.6)
Homeless 54  (2.7) 104 (4.7) 90 (3.7) 100 (3.8) 101 (3.4) 84  (2.6)
Non-Irish national 84 (4.3) 93  (4.2) 98 (4.0) 133 (5.0) 141 (4.8) 145 (4.5)
Early school leaver 274 (13.9) 340 (15.3) 369 (15.2) 412 (15.5) 477 (16.3) 448 (14.0)
Still at school 240 (12.1) 196 (8.8) 208 (8.6) 242  (9.1) 281 (9.6) 358 (11.2)
Employed (aged 16–64) 542 (29.7) 590 (28.0) 592 (25.6) 524 (20.8) 386 (13.9) 357  (11.7)
Previously treated cases 2760 2825 3144 3510 3439 4217
Median age (range) 28 (19–42) 28 (19–43) 29 (19–43) 29 (19–44) 30 (18–45) 30 (18–44)
Under 18 years 72  (2.6) 72 (2.5) 88 (2.8) 108 (3.1) 110  (3.2) 174 (4.1)
Male 1972  (71.4) 2126 (75.3) 2363  (75.2) 2517 (71.7) 2446 (71.1) 2965 (70.3)
Living with parents and/or 
family 1291  (46.8) 1343  (47.5) 1408 (44.8) 1587 (45.2) 1500 (43.6) 1846 (43.8)
Homeless 155 (5.6) 193  (6.8) 197 (6.3) 273 (7.8) 203 (5.9) 207  (4.9)
Non-Irish national 74 (2.7) 95 (3.4) 134  (4.3) 116 (3.3) 127 (3.7) 165 (3.9)
Early school leaver 685 (24.8) 678  (24.0) 749 (23.8) 889 (25.3) 821 (23.9) 945 (22.4)
Still at school 29 (1.1) 22  (0.8) 42 (1.3) 56  (1.6) 52  (1.5) 82 (1.9)
Employed (aged 16–64) 460  (16.8) 448  (16.0) 433 (13.9) 380 (11.0) 293 (8.6) 294 (7.0)
Treatment status unknown 141 184 175 154 128 169
* Age range presented is the 5th to 95th percentile (90% of cases are included within this range).
In order to illustrate trends over the reporting period, data were further examined for selected socio-
economic characteristics for two distinct time periods, comparing the period 2005–2007 with the period 
2008–2010.
Figure 12 shows the variation among new cases in the proportion of male cases and in the proportion of 
cases in employment. Overall, there was a very small decrease in the proportion of males between the 
two three-year periods, from 78% to 76%. 
Some changes were observed between males and females and the type of substances used. There was 
a decrease in the proportion of male cases reporting substances typically reported predominantly by 
males, such as opiates and cannabis. There was, however, a slight increase in the proportion of male 
cases reporting substances that were previously commonly reported by females, such as cocaine and 
benzodiazepines.
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The employment rate among cases aged 16–64 years dropped from 28% in 2005–2007 to 15% in 2008– 
2010, which is considerably lower than that in the general population (53% of the national population 
aged 15–64 were employed in 2010).18 This sharp decline in the number of cases in employment is most 
likely a direct consequence of the current economic climate and reflects the rise in unemployment in the 
general population. This has important implications for the social and occupational reintegration of drug 
users.
Figure 12 New cases: proportion of male cases and employed cases (NDTRS 2005–2010)
Figure 13 presents a breakdown of new cases by age group for the two time periods. The proportion of 
new cases decreased in the age groups 18 to 34 years, while it increased for the age groups 35 years and 
older. This suggests that there is a growing number of older drug users entering treatment for the first time. 
A slight increase in the proportion of cases aged under 18 was also noted.
Figure 13 New cases: age groups (NDTRS 2005–2010)
The trends related to age group differed according to the main problem substance used (Figure 14). 
There was a 79% increase in new opiate cases aged 35 or over, from 448 in 2005–2007 to 802 in 2008–
2010. In contrast, however, and although the number of cases was smaller, the age distribution of new 
benzodiazepine cases has evolved differently over the same period. An increase was noted in the younger 
age groups, with the proportion of cases under 18 years rising from 15% (27 cases) in the first period to 
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19% (67 cases) in the second period. There was a 165% increase in new benzodiazepine cases aged under 
25, from 72 in 2005–2007 to 191 in 2008–2010, with a parallel proportional decrease in the older age 
groups, especially among cases aged 45 or over.
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Figure 14 New cases: opiate cases and benzodiazepine cases by age group (NDTRS 2005–2010)
Key points – socio-economic characteristics
• The median age of cases entering treatment increased from 26 in 2005 to 28 in 2010.
• The proportion of cases who had left mainstream education before the age of 14 remained relatively 
stable at 20%, with a slight decrease to 19% in 2010.
• The proportion of all cases who reported being employed dropped from 22% in 2005 to 9% in 
2010.
• Increasing proportions of older drug users sought treatment for the first time; however, trends in this 
respect varied according to the main problem substance.
• Trends indicate an increase in older opiate users seeking treatment for the first time, while there was 
an increase in younger new benzodiazepine cases.
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Conclusions
Data on treated problem drug use provide an indication of the extent of problem drug use, the utilisation 
and the demand for treatment services, patterns of drug use and characteristics of those seeking treatment. 
The analysis presented in this paper provides service planners and policy makers with valuable information 
in order to highlight and address problem drug use. New data collected by the NDTRS at the time of exit 
from treatment will provide additional important information on the outcome of treatment, and will be 
published in future Trends Series papers, which will further assist service planners and policy makers.
The increase in the total number of people requiring drug treatment services, including previously treated 
cases returning to treatment, is a strong indication that problematic drug use remains a pressing issue 
throughout the country, often requiring long and repeated episodes of treatment over time.
Between 2005 and 2010, the total number of cases entering treatment for problem drug use increased by 
52%. New cases (those who had never been treated before) accounted for 45% of this increase. In 2010, 
opiates were the most common problem drug (57%), followed by cannabis (25%) and cocaine (9%). The 
proportion of opiate users remained stable between 2005 and 2008 but decreased slightly in the following 
two years, whereas the number of cases reporting cannabis as their main problem substance increased 
significantly. Following a steady increase to a peak in 2007, the number of cases reporting cocaine as their 
main problem substance decreased in the subsequent two years and remained stable in 2010. Among new 
cases, benzodiazepines accounted for the highest proportional increase.
The very large number of cases reporting alcohol as an additional problem substance highlights the 
strong links between alcohol and illicit substance use. As recommended in the National Drugs Strategy 
2010–2016, there is a need ‘to bring greater coherence and co-ordination to alcohol and drug issues 
at a policy, planning and operational level’ (p. 42).5
Cases appeared to start using licit and illicit substances as young teenagers, and the age at first use was 
stable over the period reviewed. However, data showed a decline in injecting behaviour and, for new 
injectors, an increasing interval between starting drug use and starting injecting. The increase in harm 
reduction services and practices over the reporting period is likely to have influenced this progress.
The figures show that there was a significant decline in employment rates among drug users, a direct 
indication of the effect of the current economic climate. These findings outline the continued importance of 
social and occupational reintegration interventions as part of the drug treatment process.
It is important to reiterate that the data recorded by the NDTRS relate to episodes of treatment, rather 
than to individual people treated each year, which is a limitation. This means that individuals may appear 
in the figures more than once if they attend more than one treatment service in a year, and may reappear 
in subsequent years. This limits the types of analysis that can be done on the data. Proposals for a unique 
health identifier as an essential element of a national health information strategy are being considered in 
the context of the forthcoming Health Information Bill. The introduction of such an identifier would be 
invaluable to the NDTRS in determining the precise numbers of people treated for problem drug and/or 
alcohol use and the types of service they attend, as well as in identifying patterns in treatment pathways. 
The growing demand for treatment for problem use of substances other than heroin, combined with 
the high proportion of cases using multiple problem substances, remains a constant challenge for service 
providers, as drug users often require multiple treatment interventions, which in turn require a high 
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degree of co-operation between services. This inter-agency approach to treatment and rehabilitation 
was highlighted as one of the priorities in the current drugs strategy.5 Supported by the drugs task force 
structure, many services are increasingly participating in local inter-agency initiatives in order to provide a 
wide range of interventions and a continuum of care for clients; for example, through the development of 
case management and key working strategies.19, 20
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